Company news
RemeGen Co. Ltd. news in 2025
RemeGen Co. Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on Canceling Some Restricted Stock Granted but Not Yet Vested in 2022 A-share Restricted Stock Incentive Plan
December 29, 2025
Announcement on Obtaining Letter of Commitment for Special Loans for Stock Repurchase from Financial Institution
December 18, 2025
Announcement on Resolutions of the 32nd Meeting of the 2nd Board of Directors
December 15, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
December 2, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 24, 2025
Announcement on Amending Some Governance Systems of the Company
November 13, 2025
Announcement on 1st Vesting Result of the 1st Vesting Period for the Reserved Grant of Type B Interests under the 2022 A-share Restricted Stock Incentive Plan and Lifting of Trading Restrictions
November 12, 2025
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
November 8, 2025
Announcement on Resolutions of the 30th Meeting of the 2nd Board of Directors
November 4, 2025
Announcement on Estimated Daily Related Party Transactions in 2026-2028
October 30, 2025
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
October 20, 2025
2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China
October 14, 2025
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
September 17, 2025
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 8, 2025
2025 Semi-annual Report
August 22, 2025
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
August 18, 2025
Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China
August 13, 2025
RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA
August 8, 2025
Announcement on Resolutions of the 2024 Annual General Meeting, the 1st A-Share Shareholders' Meeting and the 1st H-Share Shareholders' Meeting in 2025
June 26, 2025
RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
June 17, 2025
Indicative Announcement on Obtaining Term Compensation for Core Drug Patent
June 13, 2025
2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
June 2, 2025
Announcement on Completing the Issuance of H Shares
May 29, 2025
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China
May 27, 2025
Notice on Convening the 2024 Annual General Meeting, the 1st A-share General Meeting of 2025, and the 1st H-Share General Meeting of 2025
May 26, 2025
Announcement on Reply to Letter of Regulatory Inquiry from Shanghai Stock Exchange
May 23, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Shandong Jurisdiction
May 13, 2025
Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
May 12, 2025
Announcement on the First Vesting Results and Share Listing in the First Vesting Period of the Second Class A Interest and the First Class B Interest Initially Granted under the 2022 A-share Restricted Stock Incentive Plan
April 30, 2025
Report for Q1 2025
April 28, 2025
Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing
April 25, 2025
Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis
April 8, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
April 2, 2025
Announcement on 2024 Annual Profit Distribution Plan
March 27, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
March 14, 2025
Announcement on Resolutions of the 19th Meeting of the 2nd Board of Directors
February 27, 2025
Announcement on Resignation of Director and Core Technical Personnel
February 6, 2025
Annual Earnings Preannouncement for 2024
January 16, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
January 10, 2025
Announcement on the Completion of Implementing Share Increase Plan by Actual Controllers' Controlled Companies and Results of Share Increase
January 8, 2025